European Organisation of Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) Breast Cancer Module Update
The Update of the EORTC Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-Breast 23) Phase 1-3
1 other identifier
interventional
260
8 countries
9
Brief Summary
The purpose of this study is to update the EORTC QLQ Breast (BR)-23 Module. Since the development of BR-23 published 1996 the standard therapy of breast cancer has changed. New therapies brought new side effects and different impact on QoL (quality of life) are not sufficiently covered by EORTC QLQ BR-23 and an update of the module could be useful, both from clinical and scientific point of view.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable quality-of-life
Started Jun 2015
Longer than P75 for not_applicable quality-of-life
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 13, 2016
CompletedFirst Posted
Study publicly available on registry
December 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2019
CompletedSeptember 6, 2017
September 1, 2017
2.8 years
October 13, 2016
September 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quality of life
Patients under Treatment are asked to complete the questionnaire
3 years, Patients under treatment are asked once to complete the questionnaire during 3 years
Study Arms (1)
Questionnaire
EXPERIMENTALBreast cancer
Interventions
The questionnaire should be updated with respect to wording, terminology.
Eligibility Criteria
You may qualify if:
- Patients with early or metastatic breast cancer
You may not qualify if:
- Patients with second malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Medical University Graz
Graz, Austria
University Hospital Centre Rijeka
Rijeka, Croatia
Institut de Cancerologie de Lorraine
Lorraine, France
University Medical Center Regensburg
Regensburg, Germany
Instituto Nazionale Tumori Fondazione Pascale
Naples, Italy
IOV Oncologico Veneto Padova
Padivarma, Italy
Netherlands Cancer Institute - NKI
Amsterdam, Netherlands
Jagiellonian University Medical College Krakow
Krakow, Poland
Oncology Department Hospital of Navarre
Navarra, Spain
Related Publications (2)
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996 Oct;14(10):2756-68. doi: 10.1200/JCO.1996.14.10.2756.
PMID: 8874337RESULTJohnson C, Aaronson N, Blazeby JM et al. Guidelines for Developing Questionnaire Modules. 4ed.Bruessels, EORTC,2011
RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vesna Bjelic-Radisic
Medical University of Graz
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 13, 2016
First Posted
December 1, 2016
Study Start
June 1, 2015
Primary Completion
March 1, 2018
Study Completion
June 1, 2019
Last Updated
September 6, 2017
Record last verified: 2017-09
Data Sharing
- IPD Sharing
- Will not share